Trevi Therapeutics, Inc. — fact timeline

Trevi Therapeutics, Inc.: Increased authorized shares of common stock from 200,000,000 to 400,000,000 (effective 2026-06-03).

“At the Annual Meeting, the Company’s stockholders approved an amendment (the “Amendment”) to the Company’s restated certificate of incorporation (“Certificate of Incorporation”) to increase the number of authorized shares of the Company’s common stock from 200,000,0000 shares to 400,000,000 shares. The Amendment became effective upon the Company’s filing of a Certificate of Amendment to the Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on June 3, 2026”

Trevi Therapeutics, Inc. shareholders approved Amendment to increase authorized shares of common stock from 200,000,000 to 400,000,000 at the 2026-06-03 meeting.

“The Amendment to increase the number of authorized shares of common stock from 200,000,000 shares to 400,000,000 shares was approved. For: 110,453,620 Against: 3,872,599 Abstain: 17,676”

Trevi Therapeutics, Inc. shareholders approved Approval of A&R 2019 Plan at the 2026-06-03 meeting.

“The A&R 2019 Plan was approved. For: 98,140,470 Against: 1,961,030 Abstain: 101,991 Broker Non-Votes: 14,140,404”

Trevi Therapeutics, Inc. shareholders approved Advisory approval of compensation of named executive officers at the 2026-06-03 meeting.

“The compensation of the Company's named executive officers was approved, on an advisory basis. For: 98,119,461 Against: 1,982,126 Abstain: 101,904 Broker Non-Votes: 14,140,404”

Trevi Therapeutics, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-03 meeting.

“The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026 was ratified. For: 114,001,970 Against: 223,323 Abstain: 118,602”

Trevi Therapeutics, Inc. shareholders approved Election of Michael Heffernan as Class I director at the 2026-06-03 meeting.

“Michael Heffernan was elected to the Board as a Class I director for a term expiring at the 2029 annual meeting of stockholders. For: 81,567,765 Withheld: 18,635,726 Broker Non-Votes: 14,140,404”

Trevi Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income Net loss: For the first quarter of 2026, the Company reported a net loss of $13.2 million, compared to a net loss of $10.

“For the first quarter of 2026, the Company reported a net loss of $13.2 million, compared to a net loss of $10.3 million in the same period in 2025.”

Trevi Therapeutics, Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC and Leerink Partners LLC, as representatives of the several underwriters valued at $13.00 per share (effective 2026-04-16).

“On April 16, 2026, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and Leerink Partners LLC, as representatives of the several underwriters (the “Underwriters”), relating to an underwritten offering (the “Offering”) of 11,600,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”).”

Trevi Therapeutics, Inc. reported for the quarter and year ended December 31, 2025 results: net income $42.8 million.

“For the year ended December 31, 2025, the Company reported a net loss of $42.8 million, compared to a net loss of $47.9 million in 2024.”

David Clark departed as Chief Medical Officer at Trevi Therapeutics, Inc..

“David Clark, MBChB, MRCP, had stepped down as the Company’s Chief Medical Officer, effective as of September 27, 2024.”

James Cassella resigned as Member of the Board of Directors at Trevi Therapeutics, Inc..

“Dr. Cassella resigned from his position as a member of the Board of Directors of the Company, effective as of September 30, 2024.”

James Cassella was appointed as Chief Development Officer at Trevi Therapeutics, Inc..

“announced that James Cassella, Ph.D., had agreed to join the Company as its Chief Development Officer.”

Trevi Therapeutics, Inc. reported quarter ended March 31, 2024 results: net income Net loss: For the first quarter of 2024, the Company reported a net loss of $10.9 million, compared to a net loss of $6.. Guidance reaffirmed.

“Net loss: For the first quarter of 2024, the Company reported a net loss of $10.9 million, compared to a net loss of $6.4 million in the same period in 2023.”

Trevi Therapeutics, Inc. reported quarter and year ended December 31, 2023 results: net income Net loss: For the fourth quarter of 2023, the Company reported a net loss of $7.8 million, compared to a net loss of $5.. Guidance reaffirmed.

“Trevi Therapeutics, Inc., a Delaware corporation (the “Company”) announced its financial results for the quarter and year ended December 31, 2023.”

Trevi Therapeutics, Inc. reported quarter ended September 30, 2023 results: net income net loss of $7.7 million.

“For the third quarter of 2023, the Company reported a net loss of $7.7 million”

Trevi Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income Net loss: For the second quarter of 2023, the Company reported a net loss of $7.1 million, compared to a net loss of $8..

“On August 10, 2023, Trevi Therapeutics, Inc., a Delaware corporation (the "Company") announced its financial results for the quarter ended June 30, 2023.”

Trevi Therapeutics, Inc.: Amended certificate of incorporation to update director exculpation provision to include certain senior corporate officers (effective 2023-06-28).

“On June 28, 2023, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved an amendment (the “Amendment”) to the Company’s restated certificate of incorporation (“Certificate of Incorporation”) to update the existing director exculpation provision to include certain of the Company’s senior corporate officers. The Amendment became effective upon the Company’s filing of a Certificate of Amendment to the Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on June 28, 2023 (the “Certificate of Amendment”).”

Trevi Therapeutics, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm at the 2023-12-31 meeting.

“3. The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2023 was ratified. For: 44,552,048 Against: 8,732 Abstain: 16,580”

Trevi Therapeutics, Inc. shareholders approved Approval of Certificate of Amendment.

“2. The Certificate of Amendment was approved. For: 37,404,705 Against: 35,316 Abstain: 12,289 Broker Non-Votes: 7,125,050”

Trevi Therapeutics, Inc. shareholders approved Election of Class I directors.

“1. The following nominees were elected to the Board of Directors of the Company as Class I directors for terms expiring at the 2026 annual meeting of stockholders. For Withheld Broker Non-Votes James Cassella, Ph.D. 31,870,641 5,581,669 7,125,050 Michael Heffernan 37,302,433 149,877 7,125,050”

Trevi Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income a net loss of $6.4 million.

“For the first quarter of 2023, the Company reported a net loss of $6.4 million, compared to a net loss of $7.3 million in the same period in 2022.”

Trevi Therapeutics, Inc.: On April 13, 2023, the Board approved an amendment and restatement of the bylaws to eliminate the requirement to make the stockholder list available during meetings, address adjournment due to technical failures in remote meetings, and revise procedural mechanics and disclosure requirements in light (effective 2023-04-13).

“On April 13, 2023, the Board of Directors of Trevi Therapeutics, Inc. (the “Company”) approved an amendment and restatement of the Company’s amended and restated bylaws (as so amended and restated, the “Amended and Restated Bylaws”), effective immediately.”

Trevi Therapeutics, Inc. reported quarter and year ended December 31, 2022 results: net income net loss of $5.5 million.

“announced its financial results for the quarter and year ended December 31, 2022”

Trevi Therapeutics, Inc. reported quarter ended September 30, 2022 results: net income net loss of $8.3 million.

“For the third quarter of 2022, the Company reported a net loss of $8.3 million, compared to a net loss of $7.3 million in the same period in 2021.”

Lisa Delfini was appointed as Chief Financial Officer and principal financial officer at Trevi Therapeutics, Inc..

“On August 9, 2021, Trevi Therapeutics, Inc. (the “Company”) announced the hiring of Lisa Delfini, who will serve as the Company’s Chief Financial Officer and principal financial officer upon her start date of August 9, 2021.”